Buffalo will be the first city to infuse the newly-approved ALS drug Radicava.
DENT Neurologic Institute will perform the infusion treatment on a 50-year old woman and a 20-year old man from Buffalo who suffer from ALS.
Radicava was approved by the Federal Drug Administration in May, a year after Mitsubishi Tanabe Pharma Corporation submitted the drug.
The drug has been shown to slow the decline in loss of physical function for people with ALS.
This is the first treatment drug approved specifically for ALS in 22 years.
According to the ALS Association, the only other approved treatment specifically for ALS, Riluzole, was approved in 1995.
The infusion will take place at DENT at 1:30 p.m. Friday.
